Halozyme Therapeutics (HALO) announced that Johnson & Johnson (JNJ) received U.S. FDA approval of a new indication for DARZALEX Faspro co-formulated with ENHANZE, as single agent treatment of adult patients with high-risk smoldering multiple myeloma. DARZALEX Faspro is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multiple myeloma.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme Announces Pricing of $1.3 Billion in Notes
- Halozyme Extends Credit Facility and Increases Commitments
- Halozyme announces two offerings totalling $1.3B in convertible senior notes
- Halozyme Therapeutics’ Earnings Call Highlights Robust Growth
- Halozyme price target raised to $92 from $91 at Citizens JMP